Vol. 4 No. 1 (2018): Conference Proceedings: World Congress on Nutrition and Obesity Prevention Source 2017
Conference Proceedings

Poster Does Mirtazapine Interfere With Diabetes Treatment?

Duk-In Jon
Department of Psychiatry, Hallym University College of Medicine, Anyang, Korea
Won-Myong Bahk
Department of Psychiatry, Yeouido St Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea
Se-Hoon Shim
3 Department of Psychiatry, Soonchunhyang University Cheonan Hospital, Soonchunhyang University, Cheonan, Korea
Young Sup Woo
Department of Psychiatry, Yeouido St Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea
Eunsung Lim
Department of Psychiatry, Shinsegae Hospital, Kimje, Korea
Bo-Hyun Yoon
Department of Psychiatry, Naju National Hospital, Naju, Korea
Published January 1, 2018


Objectives: This study aimed to assess any negative effects that treatment with mirtazapine may incur in diabetic patients.

Methods: This study included 33 patients enrolled in naturalistic diabetes treatment that had also been diagnosed withdepression and prescribed mirtazapine for at least 6 months. Another 33 diabetic patients who had not taken any psychiatricmedicines were included as a control group. Body mass index, fasting plasma glucose, HbA1c, total cholesterol, triglyceridelevels, high-density lipoprotein, and low-density lipoprotein were assessed at baseline, 3 months, and 6 months.

Results: The dose of mirtazapine at baseline was 24.3 ± 14.0 mg/d in the mirtazapine group, and the 2 groups did not differin any baseline characteristics except for total cholesterol levels. Body mass index increased in both groups, and the change inthe mirtazapine group (1.0 ± 0.6 kg/m) was significantly greater than that in the control group (0.3 ± 0.4 kg/m, P < 0.001) at6 months. Only the control group exhibited a decrease in fasting plasma glucose, whereas both groups showed a decrease inHbA1c, low-density lipoprotein, and total cholesterol, an increase in high-density lipoprotein, and no change in triglyceridelevels. None of the differences between the groups were statistically significant.

Conclusions: In conclusion, mirtazapine increased the weight gain of diabetic patients; however, other diabetic and lipidmarkers generally did not worsen during the 6-month treatment period. These results suggest that, at least in the short term,mirtazapine is safe for diabetic patients in a stable state and are undergoing appropriate diabetic treatment.

Biography:Duk-In Jon has completed his MD and PhD from Yonsei University, Seoul, Korea. He is the professor of psychiatry in theHallym University Sacred Heart Hospital.